Charming Medical Limited Class A Ordinary Shares
NASDAQ:MCTAMedical - Care Facilities
+$0.00 today
- Market cap
- $445.55M
- Beta
- 0.00
- P/E (TTM)
- 414.6
- EPS (TTM)
- $0.07
Volume 0.00M
Average 0.87M
MCTA Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Charming Medical Limited Class A Ordinary SharesNASDAQ: MCTA
Cost of Revenue · FY2024 · year ended Mar 2025
Cost of revenue declines year over year
FY2024 cost of revenue of $2.04M fell 2.9% year over year.
Context
- Cost of revenue amounted to 32.8% of revenue in FY2024, down 2.1 pp from a year earlier.
- Cost of revenue increased in 1 of the last 2 fiscal years.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2024
- 2.04M USD
- Year-over-year change
- -2.9%
- 2-year CAGR
- +0.1%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2024 | 2025-03-31 | 2.04M | -2.9% |
| FY2023 | 2024-03-31 | 2.1M | +3.2% |
| FY2022 | 2023-03-31 | 2.04M | — |
Cost of Revenue vs competitors
How MCTA compares with its peers on the latest reported figures
- MCTA's FY2024 cost of revenue of $2.04M is the 9th highest of the 10 companies compared; the peer median is $30.63M.
- Its year-over-year change of -2.9% is the 6th highest of 9, against a peer median of +5.3%.
- Cost of revenue amounts to 32.8% of revenue for MCTA, versus a peer median of 59.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $5.98B | -0.5% | +39.0% | 102.7% | |
| LTM Mar 2026 | $803.11M | -19.9% | -26.7% | 80.2% | |
| LTM Mar 2026 | $464.88M | +35.2% | +28.6% | 85.2% | |
| LTM Mar 2026 | $83.55M | +11.1% | +4.9% | 24.3% | |
| LTM Feb 2026 | $30.63M | -12.8% | +44.9% | 38.0% | |
| LTM Mar 2026 | $29.3M | -43.5% | +4.4% | 23.0% | |
| LTM Mar 2026 | $18.66M | +353.9% | +317.5% | 476.0% | |
| LTM Mar 2026 | $12.69M | +56.1% | +158.1% | 14.0% | |
MCTACharming Medical Limited Class A Ordinary Shares | FY2024 | $2.04M | -2.9% | — | 32.8% |
| LTM Mar 2026 | $1.9M | — | — | — | |
| Peer median (excluding MCTA) | $30.63M | +5.3% | +33.8% | 59.1% | |
Competitors are the stored peer set for MCTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Mar 2023 | FY2023 Mar 2024 | FY2024 Mar 2025 |
|---|---|---|---|
| Revenue | 3.53M | 6.02M | 6.22M |
| Cost of Revenue | 2.04M | 2.1M | 2.04M |
| Gross Profit | 1.49M | 3.91M | 4.18M |
| Gross Margin | 42.3% | 65.1% | 67.2% |
| Research & Development | 0 | 0 | 0 |
| Selling, General & Admin | 1.66M | 2.35M | 2.32M |
| Operating Expenses | 2.02M | 2.91M | 2.79M |
| Depreciation & Amortization | 211.08K | 391.7K | 263.45K |
| EBITDA | (189.13K) | 1.42M | 1.72M |
| EBITDA Margin | -5.4% | 23.6% | 27.6% |
| Operating Income | (521.34K) | 1.01M | 1.39M |
| Operating Margin | -14.8% | 16.8% | 22.3% |
| Interest Income | 10.29K | 19.51K | 64.14K |
| Interest Expense | 20.26K | 26.05K | 20.87K |
| Other Income / Expenses | 100.87K | (5.35K) | 46.23K |
| Income Before Tax | (420.47K) | 1M | 1.44M |
| Pre-Tax Margin | -11.9% | 16.7% | 23.1% |
| Income Tax Expense | (84.86K) | 181.75K | 236.08K |
| Net Income | (305.12K) | 777.81K | 1.2M |
| Net Margin | -8.6% | 12.9% | 19.3% |
| EPS (Basic) | (0.02) | 0.05 | 0.07 |
| EPS (Diluted) | (0.02) | 0.05 | 0.07 |
| Weighted Avg Shares | 16.94M | 16.94M | 16.94M |
| Weighted Avg Shares (Diluted) | 16.94M | 16.94M | 16.94M |
Charming Medical Limited Class A Ordinary Shares
NASDAQ:MCTA
Intrinsic Alpha fair value
Locked
Current Price
$29.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.